Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit for securities fraud following a significant stock drop attributed to alleged violations of federal securities laws [1][3]. Group 1: Lawsuit Details - The class action lawsuit has been filed against Inspire Medical Systems and certain senior executives, with claims under Sections 10(b) and 20(a) of the Securities Exchange Act of 1934 [3]. - Investors have until January 5, 2026, to request to lead the case, which is pending in the U.S. District Court for the District of Minnesota [3]. Group 2: Company Background - Inspire Medical Systems develops an implantable medical device for treating sleep apnea, with the latest version being the Inspire V, which received FDA approval on August 2, 2024 [4]. Group 3: Stock Performance and Issues - Inspire assured investors of a timely launch for Inspire V, but failed to adequately prepare clinicians and payors, leading to delays and weak demand due to excess inventory of older devices [5][6]. - On August 4, 2025, Inspire announced an "elongated timeframe" for the Inspire V launch and reduced its 2025 earnings per share guidance by over 80%, causing the stock price to drop by $42.04, or more than 32%, from $129.95 to $87.91 per share [7][8].

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [1][2]. Group 1: Lawsuit Details - The class action lawsuit seeks to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [1]. - The complaint alleges that the launch of Inspire V was unsuccessful due to poor demand, with providers holding excess inventory and being hesitant to adopt the new treatment [2]. - Defendants are accused of making false statements regarding the successful launch of Inspire V, while failing to complete essential tasks such as training for treatment center customers and setting up necessary IT systems [2]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation in any recovery does not require serving as lead plaintiff [3]. - Class members may be entitled to compensation without incurring any out-of-pocket costs or fees [3]. Group 3: Legal Firm Background - Levi & Korsinsky, LLP has a history of securing significant settlements for shareholders and is recognized as one of the top securities litigation firms in the United States [4]. - The firm has over 20 years of experience in complex securities litigation and a dedicated team of more than 70 employees [4].

Core Insights - Inspire Medical Systems' stock has surged due to two key developments: an upgrade from Stifel analyst Jonathan Block and a significant increase in Medicare reimbursement rates for its V implant [2][3] - Despite the recent excitement, the stock is still down 38% year-to-date, indicating potential volatility and risk for investors [2] Financial Performance - Inspire's revenue has grown at an annual rate of 37.7% over the past three years, with a 10.5% year-over-year growth in the last quarter, which is notable for the medical device sector [6] - The company's operating margin is low at 4.2%, compared to the S&P 500's 18.8%, and the net income margin is only 5.0% [6][7] - Operating cash flow margin is a respectable 15.1%, indicating that the company is not depleting cash despite heavy investments for growth [7] Valuation Metrics - Inspire is currently trading at around $115, with a price-to-earnings ratio of 77.2, significantly higher than the S&P 500's 23.0, and a price-to-free cash flow ratio of 34.8 compared to the broader market's 20.2 [5] - The high valuation multiples suggest that investors are paying a premium for growth, which may not be justified given the company's limited profitability [5][11] Balance Sheet Strength - Inspire has a strong financial position with a debt-to-equity ratio of 0.9% and $323 million in cash against only $33 million in debt, providing ample room for continued investment in growth [8] - The market capitalization stands at $3.5 billion, indicating that the company is not at risk of a balance sheet crisis even in challenging market conditions [8] Market Volatility - Inspire's stock has shown significant volatility, dropping 61.6% during the inflation shock of 2022, compared to a 25.4% decline in the S&P 500, and it has not recovered to its 2023 peak of $326 [9][11] - The stock's performance during market downturns suggests that it may amplify losses compared to broader market indices [10] Future Outlook - The Medicare reimbursement increase of 50% could be a turning point for Inspire, potentially leading to higher procedure volumes and improved margins [7][12] - Investors are betting that this reimbursement boost will translate into better financial results, but caution is advised due to the stock's volatility and current valuation [13]

Core Viewpoint - Inspire Medical Systems, Inc. is facing a class action lawsuit due to alleged securities fraud related to the poor launch of its new product, Inspire V, which was marked by significant operational failures and misrepresentations to investors [3]. Group 1: Lawsuit Details - The lawsuit aims to recover losses for investors affected by alleged securities fraud between August 6, 2024, and August 4, 2025 [2]. - Defendants are accused of making false statements and concealing the poor demand for Inspire V, as providers had excess inventory and were hesitant to adopt the new treatment [3]. - Key operational failures included incomplete training for treatment center customers, lack of necessary IT systems, and failure to secure Medicare reimbursement prior to the product launch [3]. Group 2: Next Steps for Investors - Investors who suffered losses during the specified timeframe have until January 5, 2026, to request appointment as lead plaintiff, although participation does not require this role [4]. - Class members may be entitled to compensation without any out-of-pocket costs or fees [4]. Group 3: Legal Representation - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions for shareholders over the past 20 years [5]. - The firm is recognized as one of the top securities litigation firms in the United States, with extensive expertise in complex cases [5].

Core Viewpoint - A class action lawsuit has been filed against Inspire Medical Systems, Inc. and certain senior executives for securities fraud following a significant stock drop due to potential violations of federal securities laws [1][3]. Company Overview - Inspire Medical Systems develops and manufactures an implantable medical device for the treatment of sleep apnea, with the latest version being Inspire V, which received FDA approval on August 2, 2024 [4]. Allegations and Issues - The lawsuit claims that Inspire misled investors by assuring them that all necessary steps were taken for the launch of Inspire V, while in reality, the company failed to prepare clinicians and payors adequately, leading to significant delays in adoption [5][6]. - The launch of Inspire V faced weak demand as many customers had excess inventory of older devices, which contributed to the poor market reception [6]. Stock Performance - On August 4, 2025, Inspire disclosed that the launch of Inspire V would take longer than expected, resulting in a reduction of its 2025 earnings per share guidance by over 80% [7]. - Following this announcement, Inspire's stock price dropped by $42.04 per share, or more than 32%, from $129.95 on August 4, 2025, to $87.91 on August 5, 2025 [8].

Core Viewpoint - Rosen Law Firm is reminding investors who purchased common stock of Inspire Medical Systems, Inc. during the specified Class Period of the upcoming lead plaintiff deadline for a class action lawsuit [2][4]. Group 1: Class Action Details - Investors who bought Inspire Medical common stock between August 6, 2024, and August 4, 2025, may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [3]. - A class action lawsuit has already been filed, and interested parties must move the Court to serve as lead plaintiff by January 5, 2026 [4][6]. - The lawsuit alleges that Inspire Medical misrepresented key facts about its sleep apnea device, Inspire V, including market demand and necessary steps for its launch, leading to investor damages when the truth was revealed [6]. Group 2: Rosen Law Firm's Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [5]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been consistently ranked among the top firms for securities class action settlements since 2013 [5].

NEW YORK, Nov. 24, 2025 (GLOBE NEWSWIRE) -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of common stock of Inspire Medical Systems, Inc. (NYSE: INSP) between August 6, 2024 and August 4, 2025, both dates inclusive (the “Class Period”), of the important January 5, 2026 lead plaintiff deadline. SO WHAT: If you purchased Inspire Medical common stock during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingenc ...

Core Viewpoint - Inspire Medical Systems, Inc. is facing a securities class action lawsuit due to allegations of misleading investors regarding the launch of its Inspire V device for obstructive sleep apnea, which resulted in a significant stock price decline [1][5]. Group 1: Lawsuit Details - The class action lawsuit, titled City of Pontiac Reestablished General Employees' Retirement System v. Inspire Medical Systems, Inc., targets the company and its executives, representing investors who acquired stock between August 6, 2024, and August 4, 2025 [2]. - The lawsuit alleges violations of the Securities Exchange Act of 1934, claiming that management made false statements and failed to disclose operational issues that hindered the product launch [2][6]. Group 2: Allegations Against Inspire Medical - The complaint asserts that the transition to the Inspire V device was not as seamless as claimed, with management allegedly providing misleading assurances about the launch's success [3][6]. - Key allegations include poor market demand for the Inspire V, with providers holding excess inventory of the previous device and being hesitant to adopt the new version [8]. - The lawsuit highlights incomplete readiness for the rollout, with essential tasks not being completed, and logistical issues such as training and billing code delays that were not disclosed prior to the product launch [8]. Group 3: Market Reaction - On August 4, 2025, Inspire Medical admitted to an "elongated timeframe" for the Inspire V launch due to undisclosed challenges, leading to a drastic reduction in its 2025 earnings guidance by over 80% [4][5]. - Following this announcement, the company's stock price plummeted by over 32% on high trading volume, prompting the initiation of the investor class action [5].

Core Viewpoint - The company that manufactures an implant for treating sleep apnea has received an upgrade from Hold to Buy by Stifel [1] Company Summary - The implant is specifically designed for the treatment of sleep apnea, indicating a focus on addressing a significant health issue [1] Industry Summary - The upgrade reflects a positive outlook on the company's potential within the sleep apnea treatment market, suggesting increased investor confidence [1]

NEW YORK, Nov. 24, 2025 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Inspire Medical Systems, Inc. (NYSE: INSP). Accessibility StatementSkip Navigation Shareholders who purchased shares of INSP during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery. CONTACT US HERE: https://securitiesclasslaw.com/securities/inspire-medical-systems-inc-loss-su ...